PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg) POZEN Presents Phase 1 Data at Digestive Disease Week 2012 – CNBC

SAN DIEGO, May 19, 2012 (BUSINESS WIRE) — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540 …

Leave a Reply

Your email address will not be published. Required fields are marked *